GT20029: The Drug That Destroys DHT Receptors Instead of Blocking Them

There are three ways to stop DHT from damaging a hair follicle. Make less of it, which is what finasteride does. Block it from reaching the receptor, which is what clascoterone does. Or destroy the receptor itself, so there is nothing left for DHT to bind to. That third approach sounded like science fiction a decade ago. It is now a real drug called GT20029 that just finished a Phase 2 trial.

By Radiance360 · Pharmacist-Formulated · 2026

The quick answer

What is GT20029? A topical gel that uses PROTAC technology to degrade the androgen receptor protein in the scalp, rather than just blocking it. The world's first topical PROTAC compound for hair loss.

Does it work? In a Phase 2 trial of 180 men, all treated groups showed significant hair count increases at 12 weeks (p less than 0.001), with the best results from once-daily and twice-weekly schedules.

What makes it different? It may work with just twice-weekly application, a major advantage over the daily lifelong routine that current treatments demand.

When will GT20029 be available? It is advancing to Phase 3 in China. Realistic availability is 2028 or later, and it is not available anywhere today.

Three Different Ways to Fight the Same Hormone

Every effective hair loss treatment targets dihydrotestosterone, the hormone that progressively shrinks genetically sensitive follicles until they stop producing visible hair. What separates them is how they interfere with it.

Finasteride reduces DHT production by blocking the enzyme that converts testosterone into DHT, lowering the hormone throughout the body. Clascoterone, the newest arrival, blocks the androgen receptor so DHT cannot bind. Both are effective, and both leave the receptor itself intact.

GT20029 destroys the receptor. Using PROTAC technology, it tags the androgen receptor protein for the cell's disposal system, which breaks it down and clears it away. No receptor means no place for DHT to deliver its signal, regardless of how much is present. The minoxidil vs finasteride guide covers the mechanisms it aims to leapfrog.

Finasteride lowers the hormone. Clascoterone blocks the lock. GT20029 removes the lock entirely. If there is no receptor, it does not matter how much DHT is circulating, the signal has nowhere to land.

What PROTAC Technology Actually Is

PROTAC stands for proteolysis-targeting chimera, and the idea is clever.

Most drugs occupy a target, blocking its function while present; when the drug clears, the target resumes working. PROTAC molecules do not just occupy the target. They act as a connector, linking the target protein to the cell's own waste disposal machinery, the ubiquitin-proteasome system, which then destroys the tagged protein.

The elegant part: a single PROTAC molecule is not consumed. After tagging one receptor for destruction, it moves on and tags another, so one molecule can degrade many receptors. This catalytic quality is why PROTAC drugs can work at very low doses with infrequent dosing.

GT20029 is the world's first dermatological topical PROTAC compound, applying an approach mostly explored in cancer research to the androgen receptors in the scalp.

What the Phase 2 Results Showed

Here is the verified data from the peer-reviewed study, published in the Journal of Dermatological Treatment in December 2025.

From April 2023 to April 2024, the trial enrolled 180 men with androgenetic alopecia in the Hamilton-Norwood IIIv to V range (moderate to fairly advanced loss). They were split into six groups receiving GT20029 at 0.5% or 1.0%, once daily or twice weekly, for 12 weeks, or placebo.

The primary endpoint was the change in target area hair count at week 12. All four treated groups showed significant increases (p below 0.001). Two schedules, 0.5% once daily and 1.0% twice weekly, showed statistically significant improvement over their matched placebo groups (p equals 0.032 and p equals 0.023). Safety and tolerability were good.

Two things stand out. The drug produced measurable growth within 12 weeks, fast for this category. And one of the two best schedules required application only twice a week, a point that may matter more than the raw numbers.

Why Twice-Weekly Dosing Is a Bigger Deal Than It Sounds

The biggest reason hair loss treatments fail in the real world is not that they do not work, but that people stop using them.

Current treatments demand daily application, indefinitely. Miss applications and results fade. This daily-forever burden drives much of the dropout that undermines otherwise effective treatment, covered in the guide on what happens when you stop using minoxidil or finasteride.

A drug that works twice-weekly changes that equation. Two applications a week is far easier to sustain than fourteen, and easier adherence means more consistent results over the years hair loss treatment requires. GT20029's PROTAC mechanism is what makes such infrequent dosing plausible. If Phase 3 confirms it, the convenience alone could make it a preferred option.

When Will GT20029 Be Available?

This is what most people searching for GT20029 want to know.

The Phase 2 trial in China met its primary endpoint, and Kintor is advancing GT20029 to Phase 3 there alongside further US studies. Phase 3 typically takes two to three years, followed by regulatory review.

The earliest realistic availability, likely China first, is 2028 or later. The US would follow, and Pakistan later still, given the usual three-to-five year lag after initial approval elsewhere. GT20029 is not available anywhere today, and no legitimate source is selling it.

Kintor is also developing pyrilutamide (KX-826), which blocks the androgen receptor rather than degrading it. Both are progressing through late-stage trials in Asia.

What This Means If You Are Losing Hair Now

GT20029 is one of the most scientifically interesting drugs in the hair loss pipeline. It is also years from any market and further from Pakistan. Waiting is not a plan: every month of untreated hair loss allows more follicles to miniaturise, and proven treatments work best started early.

For active hair loss now, the standard remains minoxidil plus finasteride in the hair fall solution range at verified concentrations. For those whose obstacle is the daily routine GT20029 hopes to escape, consistency with a proven treatment now matters more than waiting for a convenient one later. The full hair care range keeps follicles healthy enough to benefit from whatever arrives next.

Frequently Asked Questions

What is GT20029? GT20029 is an experimental topical gel that uses PROTAC technology to degrade the androgen receptor protein in the scalp, rather than blocking it. Developed by Kintor Pharmaceutical, it is the world's first topical PROTAC compound for hair loss, and completed Phase 2 trials in China in 2025.

How does GT20029 work? It tags the androgen receptor for destruction by the cell's own waste disposal system. Without the receptor, DHT has nowhere to deliver the signal that shrinks follicles. Because one PROTAC molecule can degrade multiple receptors, the drug may work at low doses with infrequent application.

When will GT20029 be available? It is advancing to Phase 3 in China, with further US studies planned. The earliest realistic availability is around 2028 or later, likely in China first. It is not available for purchase anywhere today.

Kya GT20029 Pakistan mein milta hai? Nahi. GT20029 abhi kisi bhi mulk mein available nahi hai, sirf trials mein hai. Phase 3 China mein shuru ho raha hai. Pakistan tak pahunchne mein kaafi saal lagenge. Filhaal proven treatment, jaise minoxidil aur finasteride, hi use karna chahiye.

GT20029 finasteride se kaise different hai? Finasteride DHT banna kam karta hai. GT20029 androgen receptor ko hi khatam kar deta hai, PROTAC technology se. Jab receptor hi nahi rahega, to DHT ka signal kahin nahi ja sakta. Iska ek bara faida yeh ho sakta hai ke isay hafte mein sirf do baar lagana kaafi ho, rozana nahi.

To Sum Up

GT20029 represents the third generation of thinking about DHT. Where finasteride lowers the hormone and clascoterone blocks its receptor, GT20029 destroys the receptor outright using PROTAC technology borrowed from cancer research. Its Phase 2 trial in 180 men showed significant hair growth in 12 weeks, and one of the best results came from dosing only twice a week.

That convenience, if Phase 3 confirms it, could matter as much as the mechanism, because the treatment people stick with is the one that works. But GT20029 is still years from any market, further from Pakistan, and backed so far by a single mid-stage trial. The treatment that helps you this year is still the proven one that already exists.

Hair Fall Solution Collection | Full Hair Care Range | What Happens When You Stop Treatment